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Abstract
The growing evidences of Candida albicans (C. albicans) infections are slowly
becoming a threat to public health. Moreover, prevalence of antifungal resistant
strains of C. albicans has emphasized the need for identification of potent targets for
rational drug designing. In this aspect, traditional methods for target identification
with validation have been found to be expensive and time-consuming. To overcome
the concern, genome scale metabolic model construction provides a promising
platform that allows novel target identification in combination with subtractive
genome analysis. Thus, the chapter details current advancement in model
construction, target identification and validation. In brief, it elucidates the overall
strategies of C. albicans metabolome draft preparation, gap filling, curation of
model, simulation followed by model validation, target identification and host
pathogen interaction analysis. Finally, several examples of successful metabolic
model construction and their utility in rational drug designing also have been
discussed.
Keywords: Genome Scale Metabolic Model, Target Identification, Drug Designing,
Host-Pathogen Interaction, In-Silico Gene Knockout
1. Introduction
Candida albicans (C. albicans) is an opportunistic fungal pathogen that lives in
equilibrium with normal microbial flora of healthy individual [1]. As commensal, it
colonizes on the mucosal surface of oral, respiratory, gastrointestinal and genito-
urinary tract. But on transformation into pathogen, it breaches the protective bar-
rier in imunocompromised patients and cause candidiasis [2, 3]. Over 90% patients
of cancer and HIV endure with orophryngeal candidiasis whereas vulvovaginal
candidiasis distressed 138 million women per year [4, 5]. Candidemia is the most
recurrent nosocomial infection acquiring up to 15% infections of blood with mor-
tality rate from 40 to 70% [6]. Consequently, candidiasis has become the most
common fungal infections responsible for increased mortality and morbidity
worldwide.
For the treatment of candidiasis, limited number of antifungals has been
approved for clinical use. These antifungals categorize into four major classes -
azoles, polyenes, echinocandins, and pyrimidine analogs [7]. Azole and
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echinocandins precisely target the enzymes liable for synthesis of cell membrane or
cell wall while polyenes directly bind to membrane proteins that maintain the
osmolarity of the cell. In addition, Pyrimidines analogs are the sole antifungals that
target the pathogen’s genome rather than proteome [8, 9]. Consequently, the anti-
fungals disturb the integrity of cell directly or indirectly which ultimately leads to
the death of the pathogen (Figure 1).
C. albicans still represents itself as an emergent pathogen due to the side effects
associated with such as RBCs toxicity, nephrotoxicity, hepatotoxicity, arrhythmias,
cardiotoxicity and genitointestinal disturbances [10, 11]. Moreover, the drug resis-
tance has also increased the complexity of the disease. The reason behind resistance
is the prolonged or discriminated use of antifungals. The resistance mechanism
involves the hyperactivity of efflux pumps, mutation in targeted genes and metab-
olites bypass [12, 13]. Thus, C. albicans have different resistance pattern against the
diverse antifungals that lift up the difficulty level during the management of
Figure 1.
Antifungal Drug Discovery and Resistance. A) Since 1990s, polyenes, pyrimidine analogs, azoles,
echinocandins, and allylamines, morpholines, thiocarbamates has been approved for treatment of C. albicans
infection. Nystatin and 5-flucytosine binds to membrane ergosterol and thymidylate-synthetase, respectively that
leads to the leakage of osmotic constituents. Azoles inhibit the synthesis of ergosterol by interrupting the activity of
lanosterol-α-demethylase. Echinocandins halts the participation of (1,3) β-D-glucan synthase in glucan
synthesis. Allylamines and thiocarbamates block the oxidation of squalene. Consequently, leads to the death of
cell. B) Now, drug resistance has come into picture. Mechanism of resistance involves (1) overexpression of
target product, (2) modification of target enzyme, (3) Hyperactivation of multi-drug pump, (4) Production of
cell wall Barrier, (5) Adaption to stress response or metabolic bypass, (6) Inactivation of Drug.
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infection. On the other aspect, significant homology of drug targets with human
genes/protein, fitness traits and survival strategies such as secretion of hydrolytic
enzymes, morphogenetic switch, adhesion to surface and formation of biofilm
make this pathogen hard to kill. Thus, the scenario emphasizes the need of the novel
drug designing i.e. effective against resistant strain of C. albicans and easily accessi-
ble with less or no side effects [14–18].
Effective drug designing could be possible only after the (i) identification and
(ii) validation of potential target. In silico and in vitro approaches have been
attempted for the identification and validation of novel targets of C. albicans
followed by drug designing. Traditional methods of target identification with
experimental validation (growth assay, enzyme inhibition assay, gene knockout,
yeast to hybrid system, RNA interference) have been expensive, time-consuming
and more focused towards few genes instead of whole genome. To reduce the time
and cost, various in silico approaches such as subtractive genomics, comparative
genomics, machine learning and inverse docking has been performed for novel
target identification [19–21]. But a reliable approach is still required for proposed
drug target validation.
The present chapter introduces the advancement in reconstruction and analysis
of genome scale metabolic model (GSMM) which provides a platform that offers
the opportunity to mimic the biological environment of pathogen into a machine to
validate the essentiality of the target for the survival of pathogen. “Gene-Protein-
Reaction” association in GSMM establishes its importance as a hub for validation of
targets while stoichiometry matrix of model helps to depict the linkage information
of metabolites to each reaction. If the inhibition of a particular metabolite shows a
negative effect on growth of pathogen, it ensures the essentiality of the gene.
Additionally, the approach also allows identification of the effect of inhibition
on whole metabolome of pathogen. The GSMM can be used independently or in
combination with different approaches (high throughput transcriptome profiling
and subtractive genomics approach) (Figure 2) [19, 20, 22, 23].
Figure 2.
GSMM as a central approach for target identification and validation. In silico approaches such as (1)
Transcriptome data analysis, (2) Genome Scale Metabolic Reconstruction (GSMM), (3) Subtractive &
Comparative Genomics and (4) Integration of genomics variants dataset of pathogen are widely used for target
identification and validation. Among these, GSMM serves as a central approach which can used independently
or in combination with these approaches. Gene-protein-reaction association and in silico gene knockout feature
of GSMM make it reliable and standard approach to validate the putative targets via monitoring the impact of
gene deletion on biomass of the system. Further, prioritization of proposed genes can be done by host-pathogen
interaction analysis and protein-protein interaction analysis.
3
Metabolic Network Modeling for Rational Drug Design against Candida albicans
DOI: http://dx.doi.org/10.5772/intechopen.96749
2. Genome scale metabolic model reconstruction
A genome scale metabolic model (GSMM) is a computationally designed frame-
work of microorganism that allows an efficient and comprehensive annotation of the
metabolic functions of an organism, integrated with large-scale omics datasets and the
study ofmicrobe-host interactions [24, 25]. In brief, it describes gene-protein-reaction
association of organism that mimics the biological condition in a machine to under-
stand the genetic engineering, protein–protein interaction and evolutionary traits of
organism [26]. Consequently, it generates forecast ranging from lethality of patho-
gen’s gene to the dynamics engaged in defense mechanism of host towards infection.
As genome-scale metabolic model reconstruction become the more standard
approach, the requirement of in-silico, automated tool turn out to be more perceptible
to design and analyze these kinds of networks [27, 28]. Furthermore, availability of
the whole genome of the pathogen also encourages the construction of in silico
models. The Recent examples also have shown the potential of these models in the
quest for novel drug targets in pathogenic organisms [29–33]. Kim et al., 2009
emerged a model of multi drug resistant A. baumannii and find the essential novel
targets for therapeutic implications. Abdel-Haleem et al. in 2018, described the
reconstruction of genome-scale metabolic models for five life cycle stages of Plasmo-
dium falciparum, enabling the identification of potential drug targets that could be
used as both, anti-malarial drugs and transmission-blocking agents [34]. Reinksma
et al., 2019 developed combine model ofM. tuberculosis and human to understand the
metabolic state of pathogen during infection. Subsequently, Reinksma and team also
assessed the effect of increasing dosages of drugs targeting metabolism on the meta-
bolic state of the pathogen and predict resulting metabolic adaptations and flux
rerouting through various pathways [35]. Similarly, Nouri et al., 2020 designed a
comprehensive model of Z. mobilis to find the target for metabolic engineering
applications [36]. Thus, design of C. albicans would also be the strong platform to
understand its metabolic state in distinct adverse conditions that helps to identify and
validate the target for novel drug design even against the resistant strains.
3. Experimental design for C. albicans model
Construction of a model involved 4 major steps: 1) Preparation of Draft; 2)
Manual curation; 3) Generation of mathematical model; 4) Network evaluation and
analysis [37]. In brief, draft preparation (50%) consist gene annotation of pathogen’s
genome that further map with data reported in literature. Manual curation (20%)
considers the manual refinements and re-evaluation of draft due to the presence of
annotations having low confidence score retrieved from organism unspecific bio-
chemical databases that may affect the behavior of pathogenic model. Collection of
data for growth condition and biomass composition also is the part of this stage.
Generation of mathematical model (10%) is fully automated and includes the con-
version of refined draft into mathematical model. Fourth stage comprises the verifi-
cation, evaluation and validation of model that leads to the identification and
fulfillment of network gaps by repeating stages 2 & 3 until the gap fill is accomplished.
The complete protocol of the genome scale metabolic model reconstruction of
C. albicans is shown in Figure 3. The protocol consists of a set of methods that are
introduced in sequence but can be combined in a multitude of ways.
3.1 Hardware and software
A 64 bit computer of 8 GB RAM with stable internet connection is desired for
drafting a model till analysis. MATLAB vR2014b (https://www.mathworks.com/
4
Candida albicans
products/matlab.html) or above, COBRA Toolbox v3.0 or above, Pathway Tools v
22.5 are required to accomplished the reconstruction [38–40].
Steps:
# Matlab Installation (v2014 or above)
> > Download ! Extract ! Click on Setup ! Install with or without Internet ! Next ! Accept
license agreement ! Next ! Provide installation key ! Next ! Choose Installation Type ! Next !
Specify installation folder ! Next ! Provide license file location ! Next ! Select installation options
! Confirm the Installation ! Finish
# CobraTool box Installation
> > Download i) git ii) curl (v7.0 or above) and iii) CobraTool box (v3.0 or above)
> > First Install git: extract ! Click on Setup ! choose default settings except adjusting your PATH
environment (select use git and optional unix tool from window command prompt) and configuring
Figure 3.
A flow diagram of Genome Scale Metabolic Model Reconstruction.
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the line ending conversion (choose checkout as –is, commit Unix-style line ending).
> > Install curl: Select default settings ! Just click next ! Finish
> > Install CobraTool box: Open git bash ! Run command “git clone –depth = 1 https://github.com/
opencobra/cobratoolbox.git cobratoolbox” (it will install the setup in C:
/user/username/cobratoolbox) ! open matlab ! click on set path ! select the Toolbox folder
# SBML installation
> > Download ! Extract ! Open Matlab ! Navigate to SBML toolbox folder ! Run script “run
(install.m)”.
# Pathway tool Installation
> > Download ! Click on Setup.exe ! Select the location of installation (same as cobratool
box) ! Next ! Choose location to store configuration and data file ! Next ! Verify location of
installation ! Next ! uninstall older version (if present) ! Click finish to continue ! Ok ! Create
desktop icon (optional) ! Finish
3.2 Preparation of draft
The draft reconstruction can be done manually or automatically. On manual
mode, it is very tedious and time taking process. Thus, the software such as
metaShark and PathwayTools are available which automate the draft by using
genome database (CMR, GOLD, SEED, TIGR and NCBI Entrez Gene), biochemical
database (KEGG, BRENDA, Transport DB, TCDB and PubChem) and organism-
specific database (EcoCyc, BioCyc, Metacyc and Gene Cards) [38, 41]. First, the
chapter described the draft construction with PathwayTools followed by manual
curation and biomass composition. Further, in silico activities and model analysis
illustrated using COBRA Toolbox in MATLAB [38–40].
3.2.1 Input file format
PathoLogic plugin of PathwayTool is dedicated for automated draft construction
that accepts FASTA file (.fasta), genetic-elements.dat (.dat), GenBank (.gbk) or
PathoLogic (.pf) format as input. FASTA and GenBank file formats are easily
accessible and can be retrieved from RefSeq and GenBank database while genetic-
elements.dat and PathoLogic must be prepared that defines the annotation for each
genetic element of organism. Each input file comprises at least the basic attributes
such as unique ID, name, start base, end base, function, EC number and gene
ontology.
Steps:
> > Retrieved the .fasta file and .gbk file of each chromosome of C. albicans from RefSeq (https://www.
ncbi.nlm.nih.gov/genome/?term=candida+albicans).
3.2.2 Creation of new database
Database creation is the first step of draft model construction that requires the
information like unique identifier, database name, taxonomy of organism and
database storage type etc. Consequently, the provided data is saved into organism.
dat and organism-init.dat files that indicate the initialization of new database. Once
the database has been initialized, specify the replicons of your organism i.e., the
input files of each chromosome that can be .fasta, .dat, .gbk or .pf. Thereafter,
specify the reference database of closest organism that will add the missing entities
(reactions, enzymes and metabolites) which are absent in databases linked to path-
way tool. Trial Parse operation parse the input file(s) to correct the errors present in
input file before to automate the building of new database. Finally, the removal of
6
Candida albicans
errors allows building the model. This is the focal phase of PathoLogic plugin that
perform the parsing again and generate a database for each chromosome, gene,
proteins, enzymes, metabolites of organism. Now save the organism database that
will take several minutes to complete (Figure 4, steps: 1–6).
Steps:
> > Pathway Tool ! PathoLogic (New window popup)
> > Database ! Specify Reference PGDB (S. cerevisiae or C. glabrata)
> > Database ! Create New ! Organism ID (CanCyc) ! NCBI Taxonomy ID (237561)
> > Build ! Trial Parse
> > Build ! Automated Build.
> > Database ! Save KB
3.2.3 Refinement
Refining of database includes the inferences and manual operations: 1) Probable
Enzymes involved the additional enzyme-to-reaction assignments; 2) Name
Matcher add the additional name; 3) Rescore Pathways performs the addition of
new pathways and deletion of un-established pathways; 4) Create Protein Com-
plex permit to stipulate protein complexes that involuntarily link to appropriate
reactions; 5) Assign Modified Proteins allocate the modified substrate within the
reaction encoded by gene product within the database; 6) Predict Operons allow to
choose genetic elements on the whole genome; 7) Transport Inference Parser
finds transport reaction catalyzes proteins to construct their protein complexes and
enzymatic reactions; 8) Pathway Hole Filler seal the gaps using candidate enzymes
arise during the construction; 9) Update Cellular Review draw the cellular outline
of database; 10) Consistency Checker automatically rectify the disturbances of
data constraints. Among the refinement, hole filler play the major role which can be
done mechanically or manually (Figure 5A and B). Now, resave the database and
export it for further analysis in .sbml format using the command File ! Export !
Figure 4.
A detailed Protocol of Genome Scale Metabolic Reconstruction.
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Selected reactions to SBML file. For further processing, convert the sbml model
into “CanCyc.xls” file for manual curation (Figure 4, step: 7–8).
3.3 Manual curation
Curation of model is time taking and tedious task that require special consider-
ation during performance. It concentrates on re-evaluation and refinement of
model content manually instead of mechanically. The reason behind the manual
curation is the absence of proper and complete annotation of gene and their func-
tions. In addition, the available database provides the information which is not
organism specific. Consequently, there is a chance of adding those genes or reac-
tions or metabolites which might not be the part of organism’s metabolic network
and affect the expected behavior of modeled organism. Thus, it is suggested to
curate and assemble the draft model in pathway to pathway manners using KEGG,
Gene Ontology, Candida Genome Database, UniProt and DrugBank that ultimately
facilitate the detection of gaps of the model [42–45]. Moreover, the stage also
includes the metabolic function verification, removal of generic reaction terms
(protein, electron acceptor/donor, DNA, RNA etc.), addition of charged formula of
each metabolite, inspection of reaction stoichiometry as well as directionality,
localization of gene with its related reactions, association of gene-protein-reaction,
append of transport reaction with literature support. Other than this, inclusion of
sink reaction, demand reaction, growth associated and non-growth associated
ATP maintenance reaction are also required in a model for in-silico growth of the
organism (Figure 4, step: 9).
Figure 5.
Genome-Scale Metabolic Model of C. albicans. (A) Construction of model using Pathway Tools generated the
detailed chromosome-wise description and (B) cellular overview of the model that defines the linkage among the
metabolic pathways present in model. (C) For manual curaion, sbml format of model is converted to




Biomass reaction is the engine of metabolic model as it shows the obvious effects
on model validation and strain improvement. The biomass consist of cellular com-
ponents (proteins, RNA, DNA, Lipids, Lipopolysaccharides, Peptidoglycan, Glyco-
gen, Polyamines, etc.) with its fractional constituents [46]. Estimation of total
biomass composition may not be feasible; still the determination of comparative
fraction of all precursors can be possible experimentally for log phase growing cells.
Among the biomass precursors, lipid extraction is quite tough due the presence of
different fatty acid with diverse chain length, saturation and un-saturation. After
the quantification of biomass components, data is subjected to normalization that
computes the equation of biomass (Figure 4, step: 10).
3.5 Curated model conversion to mathematical model
In this stage, model is subjected to convert the curated draft into a condition-
specific mathematical model i.e., fully automated. MATLAB and COBRA Toolbox
are widely used software for model conversion, evaluation and analysis. To convert
the model initialize the COBRA toolbox using the command “initCobraToolbox”
first, then set of optimization solvers such as Gurobi and LP. The optimization
solvers provide commanding algorithms that improvise the programming of math-
ematical models, constraint models and constraint based scheduling models. The
solver Gurobi is a default solver for LP, MILP and QP problems while GLPK is
selected for LP and MILP problems. Read the model with “xls2model” command to
verify and set the objective as well as simulation constraints to the model. Save it to
“CanCyc.xml” format.
Script to load and save the model in mathematical format is provided in
Supplementary Data 1.
3.6 Model evaluation and validation
The metabolic model designed in third stage may have some common errors: 1)
wrong reaction constraints; 2) cofactor cannot be produced or consumed; 3)
shuffling of compounds across compartments; 4) missing transport and exchange
reactions. To rectify these issues network verification, evaluation and validation
is needed. Verification and evaluation usually leads to the addition of transport
reaction, exchange reactions and metabolic function that can be done by the
repetitive process of stage 2 and 3. Thus, it is also known as iterative process that
evokes the debugging to cure errors arising computationally. The major concern is
to make a decision when to end this process which is based on the rationale of
reconstruction.
The process starts with the test of unbalanced reaction that provides the list of
unbalanced reaction in model to balance it manually. Next is to identify the dead
end metabolites that are only consumed or produced and indicates about gaps
present in the model. Removal of dead metabolites promote gap filling which is a
manual process that can be done by using the published literature, genome pathway
annotation tools (KEGG) and organism specific databases. During gap fill, all added
reactions and metabolites must be connecting to each other. This step also includes
the addition of exchange reactions and transport reaction as well. Thereafter, the
upper and lower constraints to desire medium or environmental condition required
for the growth of organism. Constraints must be varying according to the objective
of study.
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To practice the exercise of evaluation and validation, user can also download the




> > solverok = changeCobraSolver(‘glpk’,'LP’);
> >model = xls2model(CanCyc.xlsx’);
# Check biomass production
> > FBAsolution = optimizeCbModel(model,'max’)
# Test unbalances mass and charge of C, N, P and S atoms and balances them.
> > [dE E] = checkBalance(model,'C0);
> > ind = find(dE);
> > ImbalReacs_C = model.rxns(ind);
> > [dE E] = checkBalance(model,'N0);
> > ind = find(dE);
> > ImbalReacs_N = model.rxns(ind);
> > [dE E] = checkBalance(model,'P0);
> > ind = find(dE);
> > ImbalReacs_P = model.rxns(ind);
> > [dE E] = checkBalance(model,'S0);
> > ind = find(dE);
> > ImbalReacs_S = model.rxns(ind);
# Identification of metabolic dead ends and document it in excel.
> >model = changeObjective(model,'BiomassReac_1’);
> > [missingMets,presentMets] = AnalyzeGaps(‘model’);
# Filling the gap of the model.
• Search the published literature first on metabolome of C. albicans
• Give the second priority to genome annotation tools (KEGG - https://www.kegg.jp/kegg-bin/show_
organism?menu_type=pathway_maps&org=cal) and organism specific database (Candida genome
database - http://www.candidagenome.org/).
• Last precedence gives to closest organism database (Saccharomyces - https://www.yeastgenome.
org/)
• Document all the gap fill reactions with references.
• Add gap fill reaction by repeating the stage 2 till the biomass production occurs. For addition or
deletion use the command given below-
> >model_add = addReaction(model, ‘ReactionName’, ‘Reaction’);
> >model_del = removeRxns(model, ‘ReactionName’, ‘Reaction’);
• After filling the gaps, check the production of biomass of the cell as commands given below:
> > initCobraToolbox;
> > solverok = changeCobraSolver(‘glpk’,'LP’);
> >model = xls2model(CanCyc.xlsx’);
> >model = changeObjective(model,'BiomassReac_1’);
> > FBAsolution = optimizeCbModel(model,'max’)
# Set the reaction constraints of modeled organism on minimal media
• For example-check the growth of C. albicans at Glucose and oxygen
> >model = changeRxnBounds(model, ‘GLC_tx_c’, 10, ‘l’);
> >model = changeRxnBounds(model, Oxygen_Molecule_tx_c’, 10, ‘l’);
# Change the objective function according the study and simulate the model
> >model = changeObjective(model,'BiomassReac_2’);
> > FBAsolution = optimizeCbModel(model,'max’)
• Change the reaction and reaction bounds according to the aim of the study and validate the model.
‘u’ = upper bound, ‘l’ = lower bound and ‘b’ = both bound
# Validation of the model
• On different carbon sources (Glucose for example).
> > GrowthRate = 0.10;
> > CarbonIntake = 10.0;
> >model = changeRxnBounds(model,'BiomassReac_c_test_2’,GrwothRate,'b’);
> >model = changeRxnBounds(model,'GLC_tx_c’,CarbonIntkRate,'b’);
> > fba = MinOptmz
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• Similarly perform the validation of model on nitrogen and sulfur sources i.e., reported in the
literature. Draw the flux map to check the flow of carbon throughout the model.
Once the model has been developed and validated, write the model in either .
mat, .sbml or .xlsx format for further analysis (Figure 5C).
3.7 Target identification through essentiality analysis and gene knockout
Developed model can be used for novel drug target identification by prioritizing
essential genes through in silico gene knockout of single or double genes. Reaction
deletion command lists out the reactions that help the pathogen model to cultivate
too fast. On the other hand, gene knockout inhibit the particular gene of
metabolome which act as chokepoint in pathogen. Consequently, it provokes the
survival of pathogen that establishes the necessity of that gene as drug target for
therapeutic use.
# Reaction essentiality analysis
> > [EssentialReactions,NonEssentialReactions,Reactions] = ReacEssentiality(model);
# Gene essentiality analysis
• Single gene deletion
> > [EssentialGenes,NonEssentialGenes,Genes] = SingleGeneEssentiality(model);
• Double gene deletion
> > [EssentialGenes,NonEssentialGenes,Genes] = DoubleGeneEssentiality(model);
# Gene Knockout
• Single gene knockout
> > geneList = “GeneName1”;
> > [grRatioDble, grRateKO, grRateWT] = singleGeneDeleion(model, MOMA, geneList);
• Double gene knockout
> > geneList1 = “GeneName1”;
> > geneList2 = “GeneName2”;
> > [grRatioDble, grRateKO, grRateWT] = doubleGeneDeleion (model, MOMA, geneList1,
geneList2);
3.8 Host-pathogen interaction (HPI) analysis
HPI analysis comprised of five central stages: 1) reconstruction of high quality
host and pathogen model, 2) check the common reaction and metabolites of both
the model, 3) integration of the model, 4) integration testing and 5) simulation [47].
HPI model development and analysis is presented in the Figure 6. As the proto-
col for high quality model development has been described above, this section will
exclude the first stage i.e., reconstruction of model. Next is pre-integration check to
remove the violation of mass conservation. Thus, it checks the mass balance and
stoichiometric consistency on prior basis followed by the identification of overlap
features of both the models [48]. These regions are expected to be the region of
host-pathogen interaction. Thereafter, assign the unique metabolite and reaction
identifier to common metabolites and reaction respectively that promotes the
integration of both the model successfully.
Once the model has been merged, detailed integration testing required to be
carried out that ensure the linkage among the merged models. Integrity testing is
divided into functionality test suits and independence suit. Functionality suits
include the check mass balance, flux variability analysis and literature based
boundaries verification while independence suit needs to find objective function
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that assumed to be influence by the host pathogen coupling. Further, the evaluation
of function is performed to proceed towards simulation of the integrated model.
Through simulation, one can envisage the characteristics of disease or validate the
experimental data in infection circumstances using HPI model. In addition, Gene
knockout of the HPI model can potentially predict virulent genes of the pathogen
with better accuracy than the individual model. The identification of lethal gene
and knockout can be performed as similar as mentioned in the section of 3.7.
4. Advantages of GSMM of C. albicans
Genome Scale metabolic models of several pathogens have been designed and
available at Biomodel database. The potential of these models in studying whole
Figure 6.
Host-Pathogen Interaction (HPI) Analysis using GSMM. Host-pathogen interaction analysis using GSMM
includes draft construction, pre-integration model check, integration of host-pathogen models, test of integration
and simulation. Consequently, the build mathematical model can be used to evaluate the interactions of
individual components and highlight potential targets for drug development.
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metabolite organization in living cell/organism widen significant attention in sys-
tem medicine. Nevertheless, GSMM of C. albicans would provide a platform for
target identification and validation. Till date, single metabolic model (iRV781) of C.
albicans has been developed [49]. The published model, designed on the GUI
platform of merlin, found to be non-compatible with widely used system biology
platforms such as Matlab and CobraToolbox. On comparison, model of present
study explained the complete set of gene-protein-reaction associations based on
genome annotation data and experimentally obtained information. Consequently, it
allows the production of flux value for entire set of reactions. The model also
provides the opportunity to integrate the omics and kinetic data that contributed to
better understanding of metabolism of pathogen. Such progression in model devel-
opment of C. albicans permits the context–specific simulation. Additionally, the
model would be beneficial in prediction of enzyme functions, pan-reactome analy-
sis, modeling interaction among multiple cells or organism and understanding the
colonization of pathogen and disease progression in human. In future prospect,
proposed model could be used as a reference template to design the model for
resistant strain of C. albicans.
5. Conclusion
Despite the presence of distinct antifungals, current situation demands the dis-
covery of novel antifungal(s) against resistant strain of C. albicans. A successful
drug design method is reliable on when a potent target is present. Thus, a potential
strategy, approach, pipeline and tools are required to identify the druggable target.
System biology and genome scale metabolic reconstruction of infectious pathogen
offer a novel and effective approach that positively impel the research towards the
identification of drug target that could help to design a novel antifungal against all
kind of pathogenic strains of C. albicans.
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